- Home
- CBRL vs ANIP Comparison
CBRL vs ANIP Comparison
Compare CBRL & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBRL
- ANIP
- Stock Information
- Founded
- CBRL 1969
- ANIP 2001
- Country
- CBRL United States
- ANIP United States
- Employees
- CBRL N/A
- ANIP N/A
- Industry
- CBRL Restaurants
- ANIP Biotechnology: Pharmaceutical Preparations
- Sector
- CBRL Consumer Discretionary
- ANIP Health Care
- Exchange
- CBRL Nasdaq
- ANIP Nasdaq
- Market Cap
- CBRL 1.3B
- ANIP 1.4B
- IPO Year
- CBRL N/A
- ANIP N/A
- Fundamental
- Price
- CBRL $61.08
- ANIP $65.40
- Analyst Decision
- CBRL Hold
- ANIP Strong Buy
- Analyst Count
- CBRL 8
- ANIP 8
- Target Price
- CBRL $53.86
- ANIP $80.13
- AVG Volume (30 Days)
- CBRL 1.3M
- ANIP 283.5K
- Earning Date
- CBRL 06-05-2025
- ANIP 08-05-2025
- Dividend Yield
- CBRL 1.65%
- ANIP N/A
- EPS Growth
- CBRL N/A
- ANIP N/A
- EPS
- CBRL 2.58
- ANIP N/A
- Revenue
- CBRL $3,510,062,000.00
- ANIP $674,068,000.00
- Revenue This Year
- CBRL $1.97
- ANIP $30.52
- Revenue Next Year
- CBRL $1.61
- ANIP $7.40
- P/E Ratio
- CBRL $23.46
- ANIP N/A
- Revenue Growth
- CBRL 2.84
- ANIP 30.27
- 52 Week Low
- CBRL $33.86
- ANIP $52.50
- 52 Week High
- CBRL $65.43
- ANIP $77.00
- Technical
- Relative Strength Index (RSI)
- CBRL 58.45
- ANIP 58.76
- Support Level
- CBRL $59.74
- ANIP $63.80
- Resistance Level
- CBRL $63.71
- ANIP $67.42
- Average True Range (ATR)
- CBRL 3.16
- ANIP 1.75
- MACD
- CBRL 0.09
- ANIP 0.60
- Stochastic Oscillator
- CBRL 77.64
- ANIP 78.62
About CBRL Cracker Barrel Old Country Store Inc
Cracker Barrel Old Country Store Inc operates hundreds of full-service restaurants throughout the United States. The restaurants of the company are open for breakfast, lunch, and dinner, with menus that offer home-style country food. The company generates maximum revenue from the Restaurants.
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.